SG11201407696WA - Sustained delivery of molecules using peptide surfactants and uses thereof - Google Patents

Sustained delivery of molecules using peptide surfactants and uses thereof

Info

Publication number
SG11201407696WA
SG11201407696WA SG11201407696WA SG11201407696WA SG11201407696WA SG 11201407696W A SG11201407696W A SG 11201407696WA SG 11201407696W A SG11201407696W A SG 11201407696WA SG 11201407696W A SG11201407696W A SG 11201407696WA SG 11201407696W A SG11201407696W A SG 11201407696WA
Authority
SG
Singapore
Prior art keywords
international
nanostructure
molecules
street
pct
Prior art date
Application number
SG11201407696WA
Inventor
Sotirios Koutsopoulos
Shuguang Zhang
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of SG11201407696WA publication Critical patent/SG11201407696WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181511 A1 (51) International Patent Classification: A61K 9/51 (2006.01) A61K38/08 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043572 31 May 2013 (31.05.2013) English English (30) Priority Data: 61/653,782 31 May 2012 (31.05.2012) US (71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; One Cambridge Center, Kend­ all Square, Room NE18-501, Cambridge, MA 02142-1493 (US). (72) Inventors: KOUTSOPOULOS, Sotirios; 432 W. 2nd Street, Boston, MA 02127 (US). ZHANG, Shuguang; 25 Bowker Street, Lexington, MA 02421 (US). (74) Agents: HOD A, Mahreen, Chaudhry et al.; Elmore Pat­ ent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) ir, •H 00 i-H o CJ (54) Title: SUSTAINED DELIVERY OF MOLECULES USING PEPTIDE SURFACTANTS AND USES THEREOF (57) Abstract: The present invention directed is to a drug delivery composition comprising a self- assembled nanostructure and bio - logically active molecule, wherein the nanostructure comprises surfactant peptides, and wherein the biologically active molecule is encapsulated in the nanostructure. The invention also encompasses methods of administering biologically active a molecule to a sub­ ject comprising administering the drug delivery composition and methods for the preparation of said composition.
SG11201407696WA 2012-05-31 2013-05-31 Sustained delivery of molecules using peptide surfactants and uses thereof SG11201407696WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653782P 2012-05-31 2012-05-31
PCT/US2013/043572 WO2013181511A1 (en) 2012-05-31 2013-05-31 Sustained delivery of molecules using peptide surfactants and uses thereof

Publications (1)

Publication Number Publication Date
SG11201407696WA true SG11201407696WA (en) 2014-12-30

Family

ID=49673920

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407696WA SG11201407696WA (en) 2012-05-31 2013-05-31 Sustained delivery of molecules using peptide surfactants and uses thereof

Country Status (7)

Country Link
US (1) US20150147384A1 (en)
EP (1) EP2854778A4 (en)
JP (2) JP2015519374A (en)
CA (1) CA2874003A1 (en)
HK (1) HK1203157A1 (en)
SG (1) SG11201407696WA (en)
WO (1) WO2013181511A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152751A1 (en) 2013-03-14 2014-09-25 Massachusetts Institute Of Technology Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
CN106832000B (en) * 2017-01-17 2021-06-22 国家纳米科学中心 Polypeptide liposome capable of generating morphology transformation in tumor cell lysosome
AU2018364916A1 (en) * 2017-11-09 2020-06-18 Purmx Therapeutics, Inc. Therapeutic pharmaceutical composition for cancer including miRNA
EP3723726A1 (en) 2017-12-15 2020-10-21 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses in drug delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006043A1 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
JP3959453B2 (en) * 2002-03-14 2007-08-15 沖電気工業株式会社 Translation mediation system and translation mediation server
US8187621B2 (en) * 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US20090069547A1 (en) * 2007-05-01 2009-03-12 Massachusetts Institute Of Technology Stabilization of mammalian membrane proteins by short surfactant peptides
WO2008136820A1 (en) * 2007-05-01 2008-11-13 Massachusetts Institute Of Technology Stabilization of mammalian membrane proteins by short surfactant peptides
WO2009018467A2 (en) * 2007-07-31 2009-02-05 Massachusetts Institute Of Technology Bio-sensing nanodevice
WO2010014903A1 (en) * 2008-07-31 2010-02-04 Massachusetts Institute Of Technology Multiplexed olfactory receptor-based microsurface plasmon polariton detector
KR101647521B1 (en) * 2008-08-27 2016-08-10 가부시끼가이샤 쓰리디 매트릭스 Transfection agent
JP2010222338A (en) * 2009-02-27 2010-10-07 Three D Matrix:Kk Nucleic acid transfer carrier
JP2011012042A (en) * 2009-07-03 2011-01-20 Three D Matrix:Kk Sustained release carrier for nucleic acid
JP2011126855A (en) * 2009-12-15 2011-06-30 Three D Matrix:Kk Inhibitor for aggregation of protein

Also Published As

Publication number Publication date
JP2018052935A (en) 2018-04-05
US20150147384A1 (en) 2015-05-28
JP2015519374A (en) 2015-07-09
CA2874003A1 (en) 2013-12-05
HK1203157A1 (en) 2015-10-23
EP2854778A1 (en) 2015-04-08
WO2013181511A1 (en) 2013-12-05
EP2854778A4 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201408174UA (en) Antibody formulation
SG11201807912SA (en) Vaccine against rsv
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201408054RA (en) Pegylated oxm variants
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations